SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-22-011092
Filing Date
2022-09-13
Accepted
2022-09-13 16:30:52
Documents
57
Period of Report
2022-07-31

Document Format Files

Seq Description Document Type Size
1 p9722010q.htm   iXBRL 10-Q 636641
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7992
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 8067
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6085
  Complete submission text file 0001214659-22-011092.txt   3609509

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alxneuro-20220731.xsd EX-101.SCH 39230
6 XBRL CALCULATION FILE alxneuro-20220731_cal.xml EX-101.CAL 33399
7 XBRL DEFINITION FILE alxneuro-20220731_def.xml EX-101.DEF 141030
8 XBRL LABEL FILE alxneuro-20220731_lab.xml EX-101.LAB 281053
9 XBRL PRESENTATION FILE alxneuro-20220731_pre.xml EX-101.PRE 222468
51 EXTRACTED XBRL INSTANCE DOCUMENT p9722010q_htm.xml XML 477621
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 221241117
SIC: 2834 Pharmaceutical Preparations